The Board of Pharmacy has received notice of the following product recall:

LEVEL OF NOTIFICATION: Retail pharmacy

SUPPLIER: Major

| Description | Lot #s | NDC | UPC |
|---------------------------------|---|-------------|-------------|
| RANITID TAB 150MG MMP 50 | 8JE2154; 9AE2499; 9BE2863; 9CE3723; 9DE2891; 9EE2812; 8GE1921; | | 30904671651 |
| RANITID TAB 75MG MMP 30 | 9DE2721; 8JE1916; 8KE2243; 8ME2685; 9CE3317; 9EE2579; 9GE2785; 9AE2785 | 00904671546 | 30904671546 |
| Ranitidine 150mg Tablets USP | 8GE1833; 9EE2760 | 00904671624 | |
| RANITID TAB 75MG MMP 60@ | 9GE2793; 8JE1917; 8KE2245; 8ME2724; 9AE2831; 9CE3339; 9DE2747; 9EE2636; 9FE2971 | 00904671552 | 30904671552 |

Major is voluntarily recalling the above lots of Ranitidine due to possibility of presence of NDMA contaminants. This recall is to the retail pharmacy level. Affected product started shipping August 9, 2019.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.